Preeclampsia Diagnostics Market

Preeclampsia Diagnostics Market (Test Type: Blood Test, Urine Test, and Others; Product & Services: Instruments, Reagents & Consumables, and Services) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Market Outlook 2031

  • The global preeclampsia diagnostics market size was valued at US$ 1.5 Bn in 2021
  • It is projected to grow at a CAGR of 3.8% and reach US$ 2.3 Bn by the end of 2031

Analysts’ Viewpoint on Market Scenario

Preeclampsia is a pregnancy-specific, multisystem disorder characterized by hypertension (>140/90 mm Hg) accompanied by new onset of proteinuria (>300 mg in 24 hours) after 20 weeks’ gestation. Increase in prevalence of preeclampsia across the globe is estimated to propel the preeclampsia diagnostics market progress in the near future. Preeclampsia has an impact on 2% to 8% of pregnancies worldwide. Increase in awareness about this disorder and its diagnostic procedures in pregnant women is anticipated to boost preeclampsia diagnostics market expansion in the next few years. Companies operating in the market are focusing on research and development activities to develop technologically advanced products to gain revenue benefits.

Preeclampsia Diagnostics Market

Introduction

Preeclampsia is a special complication of pregnancy. A systolic blood pressure of at least 140 mm Hg or a diastolic blood pressure of at least 90 mm Hg during pregnancy, as well as protein in the urine (proteinuria), both of which appear after week 20 of pregnancy, are required for its diagnosis. If there is only newly developed hypertension, the condition is known as pregnancy-induced hypertension (without proteinuria or other signs of organ affection).

Before the 20th week of pregnancy, some women experience high blood pressure, which is known as chronic hypertension. Preeclampsia and chronic hypertension are the common hypertensive issues of pregnancy. Preeclampsia typically develops at the end of pregnancy with little to no symptoms.

A more severe form of the condition, which can include complications such as eclampsia (fits), cerebral haemorrhage (brain bleeding), pulmonary edoema (fluid collections in the lungs), kidney failure, liver damage, and serious issues with the blood clotting system, develops in about 1 in 100 women with preeclampsia.

Request a sample to get extensive insights into the preeclampsia diagnostics market

Surge in Prevalence of Preeclampsia Worldwide

Preeclampsia is a common condition in pregnant women that is becoming more prevalent globally. Preeclampsia diagnostic tests are required due to a rise in blood pressure during pregnancy brought on by changing lifestyles, poor diet, inactivity, alcohol use, and mental stress. Incidence of preeclampsia has grown in the U.S. due to risk factors including advanced maternal age, obesity, and diabetes.

According to the Centers for Disease Control and Prevention, the number of incidences of preeclampsia among childbirth hospitalizations grew from roughly 13% in 2017 to 16% in 2019, affecting at least 1 in 7 deliveries during this time.

Preeclampsia was a documented condition in about one-third of the individuals who died during hospital birth. Preeclampsia was more common (31% more likely) in hospital deliveries for women over 45. This condition was especially prevalent in rural counties (16%) and low-income ZIP codes (16%), as well as in women who gave birth in hospitals in the South (16%) or the Midwest (15%). Therefore, rapid growth in patients with preeclampsia is contributing to the preeclampsia diagnostics market progress during the forecast period.

Increase in Funding for Diagnosis and Treatment of Preeclampsia

The preeclampsia diagnostics industry is primarily driven by heavy investments in preeclampsia research and development by numerous foundations and organizations during the forecast period. For instance, the Preeclampsia Foundation and its Canada-based affiliate, Preeclampsia Foundation Canada, would each give one medical research Vision Grant, up to US$ 20,000, on February 2, 2022, to study preeclampsia and related hypertension disorders of pregnancy.

The Preeclampsia Foundation revealed on January 27, 2022, that MoMMA's Voices, a national alliance of patient advocacy groups and people with "lived experience “(or those who represent them), had received new financing from Merck for Mothers. Merck for Mothers is a global program by Merck that aims to prevent maternal deaths. Hence, increase in funding for preeclampsia research & diagnosis by governments and other organizations is anticipated to propel the preeclampsia diagnostics market development during the forecast period.

Request a custom report on preeclampsia diagnostics market

Rose in Inclination toward Blood Tests for Accurate Diagnosis of Preeclampsia

The blood test segment dominated the global market of preeclampsia diagnostics with more than 55% share in 2021. Preeclampsia can be accurately predicted by biochemical testing. The tests are extremely helpful in predicting preeclampsia both in the first trimester and in the subsequent trimesters, particularly in cases of an early beginning of the disease.

Services Segment to Hold Major Share of Global Market

Based on product & services, the preeclampsia diagnostics business is divided into instruments, reagents & consumables, and services. The services segment is projected to dominate the global market of preeclampsia diagnostics, and is anticipated to grow at a high CAGR during the forecast period. Services include expenses occurring in the diagnostic laboratory such as rent/EMI on property, staff salary, pathologist’s salary, sample collection, report printing, etc.

Rise in Preference for Hospitals for Diagnosis and Treatment of Severe Preeclampsia

The hospital segment held maximum share of the preeclampsia diagnostics industry in 2021, and is anticipated to grow at a high CAGR from 2022 to 2031. In case of severe preeclampsia, patients are more likely to opt for hospitals for diagnosis and treatment. Patients admitted to hospitals are monitored regularly by taking urine and blood samples. This is estimated to fuel the hospitals segment during the forecast period.

Regional Outlook of Global Preeclampsia Diagnostics Industry

North America accounted for dominating share of 35% of the global market in 2021. The market in the region is projected to grow at a CAGR of over 3.6% during the forecast period. Rise in awareness of preeclampsia diagnosis in pregnant women is contributing to the market growth in the region. Several organizations and major players are increasingly focusing on research and development activities to develop advanced products to detect preeclampsia. This is expected to create lucrative opportunities for market players in the North America region during the forecast period.

Asia Pacific was the fastest-growing market in 2021. The market in the region is expected to grow at a CAGR of 4.4% during the forecast period. This can be ascribed to the rise in prevalence of preeclampsia; increase in population of India and China; availability and awareness of preeclampsia tests; and improvement in healthcare infrastructure in the Asia Pacific region. Additionally, increase in awareness about preeclampsia and its treatment is expected to drive the market in the region during the forecast period.

Analysis of Key Players

The global market for preeclampsia diagnostics is consolidated, with a few leading players that control majority of the share. Most companies are investing significantly in research & development. Expansion of product portfolios and mergers & acquisitions are notable strategies adopted by key players. Key players operating in the market include Abbott Laboratories, ACON Laboratories, Inc., ARKRAY, Inc., Bio-Rad Laboratories, Inc., Cardinal Health, Danaher Corporation (Beckman Coulter, Inc.), Diabetomics, Inc., DIRUI Industrial Co., Ltd., F. Hoffmann-La Roche Ltd., Metabolomic Diagnostics Ltd., Sera Prognostics, and Siemens Healthineers AG.

Key Developments

  • In July 2022, PerkinElmer, Inc. announced that a placental growth factor (PlGF) measurement using its DELFIA Xpress PlGF 1-2-3TM kit (CE-IVD) and a soluble fms-like tyrosine kinase 1 (sFlt-1)/PlGF ratio using its DELFIA Xpress sFlt-1 kit (CE-IVD), have been included in updated diagnostic guidance issued by the United Kingdom’s National Institute for Health and Care Excellence (NICE) to help diagnose suspected preterm preeclampsia
  • In February 2020, Shuwen Biotech Co. Ltd., a China-based leader in developing innovative diagnostics products announced that PerkinElmer, Inc. would distribute Shuwen’s breakthrough diagnostic test for preeclampsia in over 100 countries around the globe, accounting for over 120 million pregnancies annually
  • In May 2019, FIGO released new guidelines to combat preeclampsia, and calls for all women to receive first-trimester screening
  • In May 2018, Metabolomic Diagnostics secured €2 Mn in European Union funding under the Horizon 2020 SME Instrument, an initiative to accelerate growth in small- and medium-sized companies. The company is all set to support the commercialization of the preterm preeclampsia test, PrePsia.
  • In September 2017, Siemens Healthineers announced that it received the CE Mark certification. The company also declared the commercial availability of its versatile Atellica Solution in Europe, the U.S., South America, and Asia. This developed for the upcoming challenges in the testing procedures in the labs.

Key players have been profiled in the market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Preeclampsia Diagnostics Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 1.5 Bn

Market Forecast Value in 2031

US$ 2.3 Bn

Growth Rate

3.8%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value

Market Analysis

It includes cross segment analysis as well as at regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

Market share analysis by company (2021)

Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials.

Format

Electronic (PDF) + Excel

Market Segmentation

  • Test Type
    • Blood Test
    • Urine Test
    • Others
  • Product & Services
    • Instruments
    • Reagents & Consumables
    • Services
  • End-user
    • Hospitals
    • Diagnostic Centers
    • Others

Regions Covered

  • North America
  • Latin America
  • Europe
  • Latin America
  • Middle East & Africa

Companies Profiled

  • Abbott Laboratories
  • ACON Laboratories, Inc.
  • ARKRAY, Inc.
  • Bio-Rad Laboratories, Inc.
  • Cardinal Health
  • Danaher Corporation (Beckman Coulter, Inc.)
  • Diabetomics, Inc.
  • DIRUI Industrial Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Metabolomic Diagnostics Ltd.
  • Sera Prognostics
  • Siemens Healthineers AG
  • Other prominent players

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global preeclampsia diagnostics market in 2021?

The market was valued at US$ 1.5 Bn in 2021

How is the global market expected to grow during 2022-2031?

It is expected to grow at a CAGR of 3.8% from 2022 to 2031

How much worth would the preeclampsia diagnostics business be in 2031?

The global market would be worth US$ 2.3 Bn in 2031

What are the prominent trends in the global preeclampsia diagnostics sector?

Surge in prevalence of preeclampsia and increase in government funding for diagnosis and treatment of preeclampsia and other pregnancy-related disorders

What is the share of the leading test type segment of the global market?

The blood test segment held largest share of 55% in 2021

Which region held major market share of preeclampsia diagnostics in 2021?

North America accounted major share of the global market in 2021

Who are the prominent players in the global market?

Abbott Laboratories, ACON Laboratories, Inc., ARKRAY, Inc., Bio-Rad Laboratories, Inc., Cardinal Health, Danaher Corporation (Beckman Coulter, Inc.), Diabetomics, Inc., DIRUI Industrial Co., Ltd., F. Hoffmann-La Roche Ltd., Metabolomic Diagnostics Ltd., Sera Prognostics, and Siemens Healthineers AG

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Preeclampsia Diagnostics Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Segment Definition

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Preeclampsia Diagnostics Market Analysis and Forecast, 2017–2031

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Key Insights

        5.1. Technological Advancements

        5.2. Disease Prevalence & Incidence Rate globally with key countries

        5.3. Regulatory Scenario by Region/globally

        5.4. Key Industry Events (Mergers, Acquisitions, Partnerships, Collaborations, etc.)

        5.5. COVID-19 Pandemic Impact on Industry

    6. Global Preeclampsia Diagnostics Market Analysis and Forecast, by Test Type

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Test Type, 2017–2031

            6.3.1. Blood Test

            6.3.2. Urine Test

            6.3.3. Others

        6.4. Market Attractiveness By Test Type

    7. Global Preeclampsia Diagnostics Market Analysis and Forecast, by Product & Services

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Product & Services, 2017–2031

            7.3.1. Instruments

            7.3.2. Reagents & Consumables

            7.3.3. Services

        7.4. Market Attractiveness By Product & Services

    8. Global Preeclampsia Diagnostics Market Analysis and Forecast, by End-user

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by End-user, 2017–2031

            8.3.1. Hospitals

            8.3.2. Diagnostic Centers

            8.3.3. Others

        8.4. Market Attractiveness By End-user

    9. Global Preeclampsia Diagnostics Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness By Country/Region

    10. North America Preeclampsia Diagnostics Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Test Type, 2017–2031

            10.2.1. Blood Test

            10.2.2. Urine Test

            10.2.3. Others

        10.3. Market Value Forecast, by Product & Services, 2017–2031

            10.3.1. Instruments

            10.3.2. Reagents & Consumables

            10.3.3. Services

        10.4. Market Value Forecast, by End-user, 2017–2031

            10.4.1. Hospitals

            10.4.2. Diagnostic Centers

            10.4.3. Others

        10.5. Market Value Forecast, by Country, 2017–2031

            10.5.1. U.S.

            10.5.2. Canada

        10.6. Market Attractiveness Analysis

            10.6.1. By Test Type

            10.6.2. By Product & Services

            10.6.3. By End-user

            10.6.4. By Country

    11. Europe Preeclampsia Diagnostics Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Test Type, 2017–2031

            11.2.1. Blood Test

            11.2.2. Urine Test

            11.2.3. Others

        11.3. Market Value Forecast, by Product & Services, 2017–2031

            11.3.1. Instruments

            11.3.2. Reagents & Consumables

            11.3.3. Services

        11.4. Market Value Forecast, by End-user, 2017–2031

            11.4.1. Hospitals

            11.4.2. Diagnostic Centers

            11.4.3. Others

        11.5. Market Value Forecast, by Country/Sub-Region, 2017–2031

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Spain

            11.5.5. Italy

            11.5.6. Rest of Europe

        11.6. Market Attractiveness Analysis

            11.6.1. By Test Type

            11.6.2. By Product & Services

            11.6.3. By End-user

            11.6.4. By Country/Sub-Region

    12. Asia Pacific Preeclampsia Diagnostics Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Test Type, 2017–2031

            12.2.1. Blood Test

            12.2.2. Urine Test

            12.2.3. Others

        12.3. Market Value Forecast, by Product & Services, 2017–2031

            12.3.1. Instruments

            12.3.2. Reagents & Consumables

            12.3.3. Services

        12.4. Market Value Forecast, by End-user, 2017–2031

            12.4.1. Hospitals

            12.4.2. Diagnostic Centers

            12.4.3. Others

        12.5. Market Value Forecast, by Country/Sub-Region, 2017–2031

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6. Market Attractiveness Analysis

            12.6.1. By Test Type

            12.6.2. By Product & Services

            12.6.3. By End-user

            12.6.4. By Country/Sub-Region

    13. Latin America Preeclampsia Diagnostics Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Test Type, 2017–2031

            13.2.1. Blood Test

            13.2.2. Urine Test

            13.2.3. Others

        13.3. Market Value Forecast, by Product & Services, 2017–2031

            13.3.1. Instruments

            13.3.2. Reagents & Consumables

            13.3.3. Services

        13.4. Market Value Forecast, by End-user, 2017–2031

            13.4.1. Hospitals

            13.4.2. Diagnostic Centers

            13.4.3. Others

        13.5. Market Value Forecast, by Country/Sub-Region, 2017–2031

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Market Attractiveness Analysis

            13.6.1. By Test Type

            13.6.2. By Product & Services

            13.6.3. By End-user

            13.6.4. By Country/Sub-Region

    14. Middle East & Africa Preeclampsia Diagnostics Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Test Type, 2017–2031

            14.2.1. Blood Test

            14.2.2. Urine Test

            14.2.3. Others

        14.3. Market Value Forecast, by Product & Services, 2017–2031

            14.3.1. Instruments

            14.3.2. Reagents & Consumables

            14.3.3. Services

        14.4. Market Value Forecast, by End-user, 2017–2031

            14.4.1. Hospitals

            14.4.2. Diagnostic Centers

            14.4.3. Others

        14.5. Market Value Forecast, by Country/Sub-Region, 2017–2031

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6. Market Attractiveness Analysis

            14.6.1. By Test Type

            14.6.2. By Product & Services

            14.6.3. By End-user

            14.6.4. By Country/Sub-Region

    15. Competition Landscape

        15.1. Market Player – Competition Matrix (By Tier and Size of companies)

        15.2. Company Profiles

            15.2.1. Abbott Laboratories

                15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.1.2. Product Portfolio

                15.2.1.3. Financial Overview

                15.2.1.4. SWOT Analysis

                15.2.1.5. Strategic Overview

            15.2.2. Danaher Corporation (Beckman Coulter, Inc.)

                15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.2.2. Product Portfolio

                15.2.2.3. Financial Overview

                15.2.2.4. SWOT Analysis

                15.2.2.5. Strategic Overview

            15.2.3. Siemens Healthineers AG

                15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.3.2. Product Portfolio

                15.2.3.3. Financial Overview

                15.2.3.4. SWOT Analysis

                15.2.3.5. Strategic Overview

            15.2.4. Cardinal Health

                15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.4.2. Product Portfolio

                15.2.4.3. Financial Overview

                15.2.4.4. SWOT Analysis

                15.2.4.5. Strategic Overview

            15.2.5. F. Hoffmann-La Roche Ltd.

                15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.5.2. Product Portfolio

                15.2.5.3. Financial Overview

                15.2.5.4. SWOT Analysis

                15.2.5.5. Strategic Overview

            15.2.6. Bio-Rad Laboratories, Inc.

                15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.6.2. Product Portfolio

                15.2.6.3. Financial Overview

                15.2.6.4. SWOT Analysis

                15.2.6.5. Strategic Overview

            15.2.7. ARKRAY, Inc.

                15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.7.2. Product Portfolio

                15.2.7.3. Financial Overview

                15.2.7.4. SWOT Analysis

                15.2.7.5. Strategic Overview

            15.2.8. Sera Prognostics

                15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.8.2. Product Portfolio

                15.2.8.3. Financial Overview

                15.2.8.4. SWOT Analysis

                15.2.8.5. Strategic Overview

            15.2.9. Metabolomic Diagnostics Ltd.

                15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.9.2. Product Portfolio

                15.2.9.3. Financial Overview

                15.2.9.4. SWOT Analysis

                15.2.9.5. Strategic Overview

            15.2.10. Diabetomics, Inc.

                15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.10.2. Product Portfolio

                15.2.10.3. Financial Overview

                15.2.10.4. SWOT Analysis

                15.2.10.5. Strategic Overview

            15.2.11. ACON Laboratories, Inc.

                15.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.11.2. Product Portfolio

                15.2.11.3. Financial Overview

                15.2.11.4. SWOT Analysis

                15.2.11.5. Strategic Overview

            15.2.12. DIRUI Industrial Co., Ltd.

                15.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.12.2. Product Portfolio

                15.2.12.3. Financial Overview

                15.2.12.4. SWOT Analysis

                15.2.12.5. Strategic Overview

    List of Tables

    Table 01: Global Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017‒2031

    Table 02: Global Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Product & Services, 2017–2031

    Table 03: Global Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 04: Global Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 05: North America Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 06: North America Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017‒2031

    Table 07: North America Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Product & Services, 2017–2031

    Table 08: North America Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 09: Europe Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 10: Europe Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017‒2031

    Table 11: Europe Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Product & Services, 2017–2031

    Table 12: Europe Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 13: Asia Pacific Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 14: Asia Pacific Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017‒2031

    Table 15: Asia Pacific Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Product & Services, 2017–2031

    Table 16: Asia Pacific Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 17: Latin America Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 18: Latin America Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017‒2031

    Table 19: Latin America Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Product & Services, 2017–2031

    Table 20: Latin America Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 21: Middle East & Africa Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017‒2031

    Table 22: Middle East & Africa Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017‒2031

    Table 23: Middle East & Africa Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Product & Services, 2017–2031

    Table 24: Middle East & Africa Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    List of Figures

    Figure 01: Global Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: Preeclampsia Diagnostics Market Value Share, by Test Type, 2021

    Figure 03: Preeclampsia Diagnostics Market Value Share, By Product & Services, 2021

    Figure 04: Preeclampsia Diagnostics Market Value Share, by End-user 2021

    Figure 05: Global Preeclampsia Diagnostics Market Value Share Analysis, by Test Type, 2021 and 2031

    Figure 06: Global Preeclampsia Diagnostics Market Attractiveness Analysis, by Test Type, 2022–2031

    Figure 07: Global Preeclampsia Diagnostics Market Value (US$ Mn), by Blood Test, 2017‒2031

    Figure 08: Global Preeclampsia Diagnostics Market Value (US$ Mn), by Urine Test, 2017‒2031

    Figure 09: Global Preeclampsia Diagnostics Market Value (US$ Mn), by Others, 2017‒2031

    Figure 10: Global Preeclampsia Diagnostics Market Value Share Analysis, By Product & Services, 2021 and 2031

    Figure 11: Global Preeclampsia Diagnostics Market Attractiveness Analysis, By Product & Services, 2022–2031

    Figure 12: Global Preeclampsia Diagnostics Market Revenue (US$ Mn), by Instruments, 2017–2031

    Figure 13: Global Preeclampsia Diagnostics Market Revenue (US$ Mn), by Reagents & Consumables, 2017–2031

    Figure 14: Global Preeclampsia Diagnostics Market Revenue (US$ Mn), by Services, 2017–2031

    Figure 15: Global Preeclampsia Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031

    Figure 16: Global Preeclampsia Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 17: Global Preeclampsia Diagnostics Market Revenue (US$ Mn), by Hospitals, 2017–2031

    Figure 18: Global Preeclampsia Diagnostics Market Revenue (US$ Mn), by Diagnostic Centers, 2017–2031

    Figure 19: Global Preeclampsia Diagnostics Market Revenue (US$ Mn), by Others, 2017–2031

    Figure 20: Global Preeclampsia Diagnostics Market Value Share Analysis, by Region, 2021 and 2031

    Figure 21: Global Preeclampsia Diagnostics Market Attractiveness Analysis, by Region, 2022–2031

    Figure 22: North America Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, 2017–2031

    Figure 23: North America Preeclampsia Diagnostics Market Value Share Analysis, by Country, 2021 and 2031

    Figure 24: North America Preeclampsia Diagnostics Market Attractiveness Analysis, by Country, 2022–2031

    Figure 25: North America Preeclampsia Diagnostics Market Value Share Analysis, by Test Type, 2021 and 2031

    Figure 26: North America Preeclampsia Diagnostics Market Attractiveness Analysis, by Test Type, 2022–2031

    Figure 27: North America Preeclampsia Diagnostics Market Value Share Analysis, By Product & Services, 2021 and 2031

    Figure 28: North America Preeclampsia Diagnostics Market Attractiveness Analysis, By Product & Services, 2022–2031

    Figure 29: North America Preeclampsia Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031

    Figure 30: North America Preeclampsia Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 31: Europe Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, 2017–2031

    Figure 32: Europe Preeclampsia Diagnostics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 33: Europe Preeclampsia Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 34: Europe Preeclampsia Diagnostics Market Value Share Analysis, by Test Type, 2021 and 2031

    Figure 35: Europe Preeclampsia Diagnostics Market Attractiveness Analysis, by Test Type, 2022–2031

    Figure 36: Europe Preeclampsia Diagnostics Market Value Share Analysis, By Product & Services, 2021 and 2031

    Figure 37: Europe Preeclampsia Diagnostics Market Attractiveness Analysis, By Product & Services, 2022–2031

    Figure 38: Europe Preeclampsia Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031

    Figure 39: Europe Preeclampsia Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 40: Asia Pacific Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, 2017–2031

    Figure 41: Asia Pacific Preeclampsia Diagnostics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 42: Asia Pacific Preeclampsia Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 43: Asia Pacific Preeclampsia Diagnostics Market Value Share Analysis, by Test Type, 2021 and 2031

    Figure 44: Asia Pacific Preeclampsia Diagnostics Market Attractiveness Analysis, by Test Type, 2022–2031

    Figure 45: Asia Pacific Preeclampsia Diagnostics Market Value Share Analysis, By Product & Services, 2021 and 2031

    Figure 46: Asia Pacific Preeclampsia Diagnostics Market Attractiveness Analysis, By Product & Services, 2022–2031

    Figure 47: Asia Pacific Preeclampsia Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031

    Figure 48: Asia Pacific Preeclampsia Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 49: Latin America Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, 2017–2031

    Figure 50: Latin America Preeclampsia Diagnostics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 51: Latin America Preeclampsia Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022-2031

    Figure 52: Latin America Preeclampsia Diagnostics Market Value Share Analysis, by Test Type, 2021 and 2031

    Figure 53: Latin America Preeclampsia Diagnostics Market Attractiveness Analysis, by Test Type, 2022–2031

    Figure 54: Latin America Preeclampsia Diagnostics Market Value Share Analysis, By Product & Services, 2021 and 2031

    Figure 55: Latin America Preeclampsia Diagnostics Market Attractiveness Analysis, By Product & Services, 2022–2031

    Figure 56: Latin America Preeclampsia Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031

    Figure 57: Latin America Preeclampsia Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 58: Middle East & Africa Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, 2017–2031

    Figure 59: Middle East & Africa Preeclampsia Diagnostics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 60: Middle East & Africa Preeclampsia Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 61: Middle East & Africa Preeclampsia Diagnostics Market Value Share Analysis, by Test Type, 2021 and 2031

    Figure 62: Middle East & Africa Preeclampsia Diagnostics Market Attractiveness Analysis, by Test Type, 2022–2031

    Figure 63: Middle East & Africa Preeclampsia Diagnostics Market Value Share Analysis, By Product & Services, 2021 and 2031

    Figure 64: Middle East & Africa Preeclampsia Diagnostics Market Attractiveness Analysis, By Product & Services, 2022–2031

    Figure 65: Middle East & Africa Preeclampsia Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031

    Figure 66: Middle East & Africa Preeclampsia Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031

Copyright © Transparency Market Research, Inc. All Rights reserved